{"product_id":"vxrt-vrio-analysis","title":"Vaxart, Inc. (VXRT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the core of Vaxart, Inc. (VXRT)'s competitive edge! Our VRIO Analysis cuts straight to the heart of its Value, Rarity, Inimitability, and Organization - the critical elements determining sustainable success. The distilled findings, summarized in \u0026amp;O4\u0026amp;, reveal precisely where this business stands in the market. Dive in below to uncover the strategic strengths that truly matter and what it means for their future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Proprietary Oral Vaccine Delivery Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Vaxart, Inc. (VXRT) and trying to figure out if that oral pill platform is a real, durable edge or just another biotech dream. Honestly, the technology itself - a needle-free vaccine that might offer better mucosal and systemic immunity while staying stable at room temperature - is a massive value driver. That stability alone cuts distribution costs dramatically, which is huge for global health initiatives. \u003c\/p\u003e\n\u003cp\u003eThe platform is the whole game for Vaxart; their entire R\u0026amp;D pipeline, from COVID-19 to norovirus, is built on exploiting this core tech. They reported Q3 2025 revenue of \u003cstrong\u003e$72.4 million\u003c\/strong\u003e, mostly from government contracts, but the R\u0026amp;D spend was heavy at \u003cstrong\u003e$75.9 million\u003c\/strong\u003e for that quarter, showing they are investing heavily to prove this platform out. \u003c\/p\u003e\n\n\u003ch\u003eVRIO Assessment of the Oral Vaccine Platform\u003c\/h\u003e\n\u003cp\u003eHere’s the quick math on how this platform stacks up against the VRIO framework. It’s not just about having a cool idea; it’s about whether you can keep competitors locked out while you execute. \u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment for Vaxart's Platform\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh: Enables needle-free vaccination, potential for superior mucosal\/systemic immunity, and room-temperature stability.\u003c\/td\u003e\n    \u003ctd\u003eNecessary for Competitive Parity\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh: A stable, recombinant oral pill platform that elicits strong immune responses is exceptionally rare in the current market.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh Cost\/Time: Requires years of specific biological engineering and formulation science that competitors cannot easily replicate overnight.\u003c\/td\u003e\n    \u003ctd\u003ePotential for Sustained Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes: The entire pipeline strategy is centered on leveraging this core technology across multiple indications.\u003c\/td\u003e\n    \u003ctd\u003eRealizing Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage and Near-Term Action\u003c\/h\u003e\n\u003cp\u003eIf the ongoing clinical data continues to validate the platform’s superiority over traditional injectables, the advantage here is \u003cstrong\u003esustained\u003c\/strong\u003e. That’s the big 'if' we watch for. The recent exclusive license agreement with Dynavax in November 2025, potentially worth up to \u003cstrong\u003e$700 million\u003c\/strong\u003e plus royalties for the oral COVID-19 candidate, is a massive organizational validation step. It shows a commercial player believes in the tech enough to commit significant capital. \u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the immediate cash position; cash, cash equivalents, and investments were down to \u003cstrong\u003e$28.8 million\u003c\/strong\u003e as of September 30, 2025, even with high Q3 revenue. Still, management projects the runway extends into the second quarter of 2027, which gives them breathing room. \u003c\/p\u003e\n\u003cp\u003eYou need to focus on the data readouts to confirm this advantage. If onboarding takes 14+ days longer than expected for the next trial phase, churn risk rises for investor confidence. \u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eCOVID-19 Phase 2b: Topline data expected late 2026.\u003c\/li\u003e\n  \u003cli\u003eNorovirus Phase 1: Positive topline data reported in Q2 2025.\u003c\/li\u003e\n  \u003cli\u003eCash runway: Projected into Q2 2027.\u003c\/li\u003e\n  \u003cli\u003eDynavax deal: Upfront payment of \u003cstrong\u003e$25 million\u003c\/strong\u003e plus equity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe next concrete step is monitoring the sentinel cohort data for the COVID-19 trial, which is anticipated in the first quarter of 2026. \u003cstrong\u003eResearch \u0026amp; Development:\u003c\/strong\u003e track the Q4 2025 R\u0026amp;D spend against the Q3 spend of $75.9 million to see if cost management is improving post-Dynavax deal.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Broad Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eVaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Filed broad domestic and international patent applications covering the core technology, specifically for oral vaccination using adenovirus and TLR3 agonists, creating a legal moat. The platform technology patents are set to expire in 2027, or later if patent term extension applies, while patents issuing from tablet vaccine formulation applications will expire in \u003cstrong\u003e2035\/2036\u003c\/strong\u003e. [cite: 5 from previous search]\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; while many biotechs have patents, Vaxart’s patents cover the specific method of oral delivery for these vaccine types, which is less common. Patenting activity in Q2 2024 showed filings concentrated in the Denmark (DK) Patent Office, accounting for nearly \u003cstrong\u003e50%\u003c\/strong\u003e of filings in that quarter, alongside filings at the European Patent Office (EPO). [cite: 5 from previous search]\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patent protection makes direct imitation legally blocked for the life of the patents. The company's ability to stop third parties depends on the extent of rights under valid and enforceable patents. [cite: 7 from previous search]\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the legal and R\u0026amp;D teams are organized to defend and expand this IP base around new constructs. General and administrative expenses were \u003cstrong\u003e$4.6 million\u003c\/strong\u003e for the second quarter of 2025, with a decrease noted in legal and other professional fees compared to the prior year period. [cite: 3 from first search]\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the patents remain in force and are successfully defended. The company’s cash, cash equivalents and investments totaled \u003cstrong\u003e$26.3 million\u003c\/strong\u003e as of June 30, 2025. [cite: 3 from first search]\u003c\/p\u003e\n\n\u003cp\u003eThe scope of the intellectual property portfolio can be partially quantified by the following data points:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Metric Category\u003c\/td\u003e\n\u003ctd\u003eSpecific Data Point\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Platform Patents (Issued)\u003c\/td\u003e\n\u003ctd\u003eClaims relating to platform technology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2023 [cite: 5 from previous search]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForeign Platform Patents (Issued)\u003c\/td\u003e\n\u003ctd\u003eRelated to platform technology and\/or vaccine candidates\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003emore than 45\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2023 [cite: 5 from previous search]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulation Patent Expiration (Approximate)\u003c\/td\u003e\n\u003ctd\u003eEarliest projected expiration for formulation patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2035\/2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor patents issuing from pending applications [cite: 5 from previous search]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment Contract Value (COVID-19)\u003c\/td\u003e\n\u003ctd\u003eMaximum value of Project NextGen award\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$456 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor Phase 2b trial funding [cite: 1 from first search]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents and investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025 [cite: 3 from first search]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Diversified Infectious Disease Pipeline\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces single-asset risk by targeting multiple high-need areas: COVID-19, norovirus (no approved vaccine), and influenza, plus an oncology asset (HPV). The COVID-19 program has an exclusive license agreement with Dynavax for potential cumulative proceeds of up to \u003cstrong\u003e$700 million\u003c\/strong\u003e plus royalties.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many clinical-stage firms focus on one or two areas, but Vaxart maintains active programs across three major prophylactic areas.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can pursue similar targets, but Vaxart has a head start in the oral delivery method for these specific diseases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the company allocates resources across these distinct programs, as seen by the Q3 2025 financial data. Research and development expenses for Q3 2025 were \u003cstrong\u003e$75.9 million\u003c\/strong\u003e, while General and administrative expenses were \u003cstrong\u003e$4.3 million\u003c\/strong\u003e. Cash, cash equivalents and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e as of September 30, 2025, with a current runway extended into the second quarter of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; pipeline diversification is good practice, but the advantage hinges on which asset reaches the market first. The COVID-19 Phase 2b trial completed enrollment of approximately \u003cstrong\u003e5,400\u003c\/strong\u003e participants as of September 30, 2025, with full trial topline data anticipated in late \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003ePipeline Asset Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\u003c\/td\u003e\n\u003ctd\u003ePhase\/Status\u003c\/td\u003e\n\u003ctd\u003eKey Statistical\/Financial Data Point\u003c\/td\u003e\n\u003ctd\u003eLatest Expectation\/Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19\u003c\/td\u003e\n\u003ctd\u003ePhase 2b (Enrollment Complete)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5,400\u003c\/strong\u003e participants enrolled as of September 30, 2025\u003c\/td\u003e\n\u003ctd\u003eTopline data expected late \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorovirus (2nd Gen)\u003c\/td\u003e\n\u003ctd\u003ePhase 1 (Enrollment Complete)\u003c\/td\u003e\n\u003ctd\u003eSecond-generation constructs showed 141% GI.1 and 94% GII.4 blocking antibody increases versus first-generation\u003c\/td\u003e\n\u003ctd\u003eTopline data expected mid-\u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfluenza (Avian)\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eCandidate was 100% protective against death in a ferret challenge model\u003c\/td\u003e\n\u003ctd\u003ePreparing to manufacture for clinical use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPV\u003c\/td\u003e\n\u003ctd\u003eTherapeutic Vaccine\u003c\/td\u003e\n\u003ctd\u003eVaxart's first immune-oncology indication\u003c\/td\u003e\n\u003ctd\u003eStatus not detailed in recent financial updates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRecent Financial Metrics (Q3 2025, as of September 30, 2025):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue: \u003cstrong\u003e$72.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss: \u003cstrong\u003e$8.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses: \u003cstrong\u003e$75.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments: \u003cstrong\u003e$28.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCOVID-19 Program Milestones and Funding:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSentinel cohort (400-person) topline data anticipated in the first quarter of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, the Company has received \u003cstrong\u003e$125.9 million\u003c\/strong\u003e of cash payments associated with the BARDA Project NextGen award.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Advanced COVID-19 Phase 2b Trial Execution\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe Phase 2b trial execution represents a significant de-risking event by providing large-scale human data on safety and efficacy for the lead asset against an approved mRNA comparator. The trial is designed to determine relative efficacy, safety, and immunogenicity in adults previously immunized against COVID-19 infection.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Component\u003c\/td\u003e\n\u003ctd\u003eTarget\/Actual Number\u003c\/td\u003e\n\u003ctd\u003eStatus\/Milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSentinel Cohort Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e participants (\u003cstrong\u003e200\u003c\/strong\u003e Vaxart \/ \u003cstrong\u003e200\u003c\/strong\u003e Comparator)\u003c\/td\u003e\n\u003ctd\u003eEnrollment completed in December 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain Cohort Size\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e10,000\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eFirst patient dosed in May 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Progress (Main Cohort)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e5,400\u003c\/strong\u003e participants enrolled as of September 2025\u003c\/td\u003e\n\u003ctd\u003eEnrollment halted due to subsequent stop work order in August 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSentinel Cohort Data Readout\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAnticipated in the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTopline Data Readout (Full Trial)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAnticipated in \u003cstrong\u003elate 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eCompleting a Phase 2b trial of this size for an oral vaccine candidate is a major, rare milestone in the industry, particularly one designed as a head-to-head comparison against an established injectable vaccine.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eReplicating the specific trial design, the pace of enrollment achieved prior to the August 2025 work stoppage, and the associated government backing is difficult. The project is funded with federal funds from BARDA under Other Transaction (OT) number \u003cstrong\u003e75A50123D00005\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe operational readiness to execute large studies is evidenced by the lifting of a government stop work order in \u003cstrong\u003eApril 2025\u003c\/strong\u003e, which enabled the subsequent screening and dosing of the 10,000-participant portion. The Data Safety Monitoring Board (DSMB) recommended the study proceed without modifications based on the 30-day safety data from the 400-person sentinel cohort.\u003c\/p\u003e\n\u003cp\u003eFinancial and funding milestones supporting execution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 2b NextGen COVID-19 clinical trial is valued at up to \u003cstrong\u003e$456 million\u003c\/strong\u003e through the Rapid Response Partnership Vehicle under BARDA.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, the Company had received \u003cstrong\u003e$125.9 million\u003c\/strong\u003e of cash payments associated with this award.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company entered an exclusive license agreement with Dynavax in November 2025, receiving an upfront license fee of \u003cstrong\u003e$25 million\u003c\/strong\u003e plus a \u003cstrong\u003e$5 million\u003c\/strong\u003e equity investment.\u003c\/li\u003e\n\u003cli\u003eWith the Dynavax upfront payment, Vaxart anticipated cash runway into the \u003cstrong\u003esecond quarter of 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e; it will shift to the asset that reports positive topline data in \u003cstrong\u003elate 2026\u003c\/strong\u003e, which is contingent on the continuation of the trial following the August 2025 stop work order and subsequent dialogue with government partners.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Second-Generation Norovirus Data\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Phase 1 data announced in September 2025 showed second-generation constructs induced robust increases in fecal IgA, which correlated with protection in prior studies.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eConstruct\/Dose\u003c\/th\u003e\n\u003cth\u003eStrain\u003c\/th\u003e\n\u003cth\u003eFecal IgA Fold Increase Over Baseline\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond-Generation (High Dose)\u003c\/td\u003e\n\u003ctd\u003eGII.4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond-Generation (High Dose)\u003c\/td\u003e\n\u003ctd\u003eGI.I\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond-Generation (Low Dose)\u003c\/td\u003e\n\u003ctd\u003eGII.4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond-Generation (Low Dose)\u003c\/td\u003e\n\u003ctd\u003eGI.I\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst-Generation (High Dose in same study)\u003c\/td\u003e\n\u003ctd\u003eGII.4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst-Generation (High Dose in same study)\u003c\/td\u003e\n\u003ctd\u003eGI.I\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe first-generation constructs demonstrated a statistically significant \u003cstrong\u003e30%\u003c\/strong\u003e relative reduction in infection compared with placebo in a Phase 2b challenge study.\u003c\/p\u003e\n\u003cp\u003eNorovirus represents a global burden of \u003cstrong\u003e685 million\u003c\/strong\u003e infections annually and an economic impact estimated at over \u003cstrong\u003e$10 billion\u003c\/strong\u003e in the U.S.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; demonstrating a strong correlate of protection for an oral vaccine against norovirus is a breakthrough, given the lack of approved vaccines.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the specific second-generation construct and the IgA correlation data are unique to Vaxart’s internal research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the company is actively using this data to explore partnership opportunities for the next clinical step.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompany intends to conduct a Phase 2b safety and immunogenicity study potentially beginning as early as the second half of 2025, followed by an End of Phase 2 meeting with the FDA.\u003c\/li\u003e\n\u003cli\u003ePotential Phase 3 trial could begin as early as 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway extended into the \u003cstrong\u003esecond quarter of 2027\u003c\/strong\u003e following a partnership agreement.\u003c\/li\u003e\n\u003cli\u003eThird Quarter 2025 revenue was \u003cstrong\u003e$72.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$4.9 million\u003c\/strong\u003e for the third quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if this data leads to a successful, first-to-market norovirus vaccine.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: BARDA\/Project NextGen Funding Relationship\n\u003c\/h2\u003e\n\u003cp\u003e\nThe relationship with the Biomedical Advanced Research and Development Authority (BARDA) under Project NextGen provides a critical resource for Vaxart, Inc.'s clinical development pipeline.\n\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nAccess to substantial non-dilutive funding, with potential for up to \u003cstrong\u003e$460.7 million\u003c\/strong\u003e under the award, which directly funds expensive clinical work like the COVID-19 trial.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe award is part of the $5 billion Project NextGen initiative.\n\u003c\/li\u003e\n\u003cli\u003e\nThe funding supports a Phase 2b comparative study evaluating the oral pill COVID-19 vaccine candidate against an approved mRNA injectable vaccine.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nHigh; securing large, multi-year government contracts like this is rare for smaller biotechs and provides a crucial financial buffer.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nVaxart was the first U.S. company to complete a Phase 2 clinical trial of an oral vaccine for COVID-19.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nLow; this relationship is built on years of trust and successful navigation of government contracting processes.\n\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nYes, this funding stream is integrated into their operational budget.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount \/ Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Award Value\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$460.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Funding Available\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$65.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemainder Contingent on Study Progress\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$387.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Preparation Award\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.27 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2b Study Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10,000-subject\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Transaction (OT) Number\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75A50123D00005\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nTemporary; the advantage lasts as long as the contract milestones are met and the funding remains available.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nInterim analysis for vaccine efficacy anticipated as early as the first quarter of 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nApproval received to initiate dosing in the 10,000-participant portion in the second quarter of 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Exclusive License Agreement with Dynavax\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The November 2025 Exclusive License Agreement with Dynavax for the oral COVID-19 vaccine candidate provides significant financial enhancement and de-risking for the platform asset.\u003c\/p\u003e\n\u003cp\u003eThe financial structure of the deal includes immediate and contingent payments:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eAmount\/Rate\u003c\/th\u003e\n\u003cth\u003eTiming\/Condition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront License Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon execution of the agreement in November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon execution, at a premium to market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Future Regulatory Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$195 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent upon Dynavax electing to assume development post-Phase 2b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Future Net Sales Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$425 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent upon Dynavax electing to assume development post-Phase 2b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Cumulative Proceeds (Excluding Royalties)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$645 million\u003c\/strong\u003e (Upfront\/Equity + Milestones)\u003c\/td\u003e\n\u003ctd\u003eIncludes \u003cstrong\u003e$30 million\u003c\/strong\u003e immediate cash\/equity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties on Future Net Sales\u003c\/td\u003e\n\u003ctd\u003eTiered rates in the \u003cstrong\u003elow-to-mid teens\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent upon commercialization by Dynavax\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAs of September 30, 2025, Vaxart’s cash, cash equivalents, and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e. The receipt of the upfront payment from Dynavax directly supports the company’s projection that its cash runway extends into \u003cstrong\u003eQ2 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The agreement is a significant validation event for Vaxart’s proprietary oral vaccine platform (VAAST) while the COVID-19 asset was still in Phase 2b development.\u003c\/p\u003e\n\u003cp\u003eKey operational and clinical data points underpinning the deal's value include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrollment completion for the COVID-19 Phase 2b trial with approximately \u003cstrong\u003e5,400\u003c\/strong\u003e participants.\u003c\/li\u003e\n\u003cli\u003eTopline data anticipated from the 400-person sentinel cohort in \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTopline data for all participants anticipated in \u003cstrong\u003elate 2026\u003c\/strong\u003e or \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBARDA funding continues to support follow-up for the enrolled subjects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific combination of the upfront payment, equity investment, milestone structure, and the selection of Dynavax as a major partner for a platform asset at this stage is unique to Vaxart’s specific negotiation success and timing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The deal is highly synergistic with Vaxart's organizational need for non-dilutive capital to reach critical clinical milestones.\u003c\/p\u003e\n\u003cp\u003eFinancial context from Q3 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue for Q3 2025 was \u003cstrong\u003e$72.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$4.9 million\u003c\/strong\u003e for Q3 2024.\u003c\/li\u003e\n\u003cli\u003eNet loss per share for Q3 2025 was \u003cstrong\u003e$0.04\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe agreement allows Vaxart to retain full operational and financial responsibility through the completion of the Phase 2b trial and the subsequent End of Phase 2 meeting with the FDA, after which Dynavax has the option to assume responsibility, potentially triggering an additional \u003cstrong\u003e$50 million\u003c\/strong\u003e payment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Extended Cash Runway\n\u003c\/h2\u003e\n\u003cp\u003e\nThe extended cash runway is primarily supported by the recent strategic licensing agreement with Dynavax and prior government funding.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\/Period\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Financial Results\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtended Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ2 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-Dynavax Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDynavax Upfront License Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePart of Exclusive License Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDynavax Equity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt a premium to market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Total Dynavax Value\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$700 million\u003c\/strong\u003e plus royalties\u003c\/td\u003e\n\u003ctd\u003eIncludes milestones and sales payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA Payments Received (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$125.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAssociated with Project NextGen Award\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe financial state supporting the runway includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe runway extends into \u003cstrong\u003eQ2 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nCash, cash equivalents, and investments totaled \u003cstrong\u003e$28.8 million\u003c\/strong\u003e as of September 30, 2025, with the runway now extending into \u003cstrong\u003eQ2 2027\u003c\/strong\u003e, reducing immediate financing pressure.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nMedium; many clinical-stage firms have a runway of \u003cstrong\u003e12-18 months\u003c\/strong\u003e; extending past two years is a strong position.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nLow; this specific runway is a direct result of the \u003cstrong\u003e$700 million\u003c\/strong\u003e potential Dynavax deal and prior BARDA payments.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nYes, the new CFO, Jeroen Grasman, appointed in \u003cstrong\u003eMay 2025\u003c\/strong\u003e, is clearly focused on managing this runway effectively.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nTemporary; this is a financial state, not a core asset, and it will be consumed by R\u0026amp;D burn.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVaxart, Inc. (VXRT) - VRIO Analysis: Operational Adaptability and Leadership Transition\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to implement a workforce restructuring (initial \u003cstrong\u003e10%\u003c\/strong\u003e reduction in Q1 2025) following the initial COVID-19 trial pause, and then successfully resume the large trial, demonstrates organizational toughness. This was followed by an additional workforce reduction of a further approximately \u003cstrong\u003e21%\u003c\/strong\u003e in Q2 2025 due to a second stop-work order on August 5, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; successfully executing a workforce reduction from a base of \u003cstrong\u003e105\u003c\/strong\u003e employees at end-of-2024, immediately ramping up screening for the \u003cstrong\u003e10,000-participant\u003c\/strong\u003e trial after the initial pause, and then facing a second operational freeze highlights a rare sequence of high-stakes internal\/external management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this reflects specific internal leadership decisions regarding cost alignment and employee morale management under dual regulatory uncertainty, which are difficult to copy precisely.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, evidenced by the smooth appointment of new CFO Jeroen Grasman, effective \u003cstrong\u003eMay 19, 2025\u003c\/strong\u003e, succeeding Phillip Lee (who remained until \u003cstrong\u003eJune 1, 2025\u003c\/strong\u003e), and the immediate resumption of screening\/dosing for the Phase 2b trial following the first stop-work order lift.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; operational efficiency, demonstrated by the ability to align costs (cash runway extended to \u003cstrong\u003eQ1 2026\u003c\/strong\u003e based on \u003cstrong\u003e$26.3 million\u003c\/strong\u003e cash at Q2-end 2025) while managing trial progression, is critical but requires constant maintenance.\u003c\/p\u003e\n\u003cp\u003eKey Operational and Financial Metrics During Transition Period:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Workforce Cut\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eFollowing initial HHS stop-work order on February 21, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Workforce Cut\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eImplemented after the second stop-work order on August 5, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CFO Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 19, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAppointment of Jeroen Grasman.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2b Trial Size (Target)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10,000\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eResumed screening after initial pause.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2b Enrollment (at 2nd Pause)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e5,000\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eHalted on August 5, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal Funding Amount\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$460.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAwarded under BARDA\/Project NextGen.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$39.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $6.4 million in Q2 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational Resilience Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial COVID-19 trial cohort size: \u003cstrong\u003e400\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eDosing initiated in 10,000-participant portion: \u003cstrong\u003eMay 27, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData Safety Monitoring Board (DSMB) determined study could proceed without modification in July 2025.\u003c\/li\u003e\n\u003cli\u003eNew CFO Jeroen Grasman received an option to purchase \u003cstrong\u003e1,000,000\u003c\/strong\u003e shares.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516280201365,"sku":"vxrt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vxrt-vrio-analysis.png?v=1740228311","url":"https:\/\/dcf-model.com\/pt\/products\/vxrt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}